Subject(s)
Asthma , Dermatitis, Atopic , Heterocyclic Compounds, 3-Ring , Rhinitis, Allergic , Adult , Female , Humans , Male , Middle Aged , Asthma/drug therapy , Asthma/complications , Dermatitis, Atopic/drug therapy , Dermatitis, Atopic/complications , Heterocyclic Compounds, 3-Ring/therapeutic use , Retrospective Studies , Rhinitis, Allergic/drug therapy , Rhinitis, Allergic/complications , Severity of Illness IndexABSTRACT
Summary: Background. International guidelines suggested skin tests with Polyethylene-glycol (PEG) and polysorbate 80 (PS-80), to investigate a possible hypersensitivity to these excipients either to identify subjects at risk of developing allergic reactions to Covid-19 vaccines, or in patients with suspected IgE mediated hypersensitivity reactions (HR) to the Covid-19 vaccine. The main purpose of this study was to investigate the prevalence of PEG and PS sensitization in patients with a clinical history of HR to drugs containing PEG/PS and in patients with a suspected Covid-19 vaccine immediate HR. Methods. This was a multicenter retrospective study conducted by allergists belonging to 20 Italian medical centers. Skin testing was performed in 531 patients with either a clinical history of suspected hypersensitivity reaction (HR) to drugs containing PEG and/or PS-80 (group 1:362 patient) or a suspected HR to Covid-19 vaccines (group 2: 169 patient), as suggested by the AAIITO/SIAAIC guidelines for the "management of patients at risk of allergic reactions to Covid-19 vaccines" [1]. Results. 10/362 (0.02%) had positive skin test to one or both excipients in group 1, 12/169 (7.1%) in group 2 (p less than 0.01). In group 2 HRs to Covid-19 vaccines were immediate in 10/12 of cases and anaphylaxis occurred in 4/12 of patients. Conclusions. The positivity of skin test with PEG and or PS before vaccination is extremely rare and mostly replaceable by an accurate clinical history. Sensitization to PEG and PS has to be investigated in patients with a previous immediate HR to a Covid-19 vaccine, in particular in patients with anaphylaxis.
Subject(s)
Anaphylaxis , COVID-19 , Hypersensitivity, Immediate , Humans , Polysorbates/adverse effects , Polyethylene Glycols/adverse effects , COVID-19 Vaccines/adverse effects , COVID-19/epidemiology , COVID-19/prevention & control , Excipients/adverse effects , Anaphylaxis/diagnosis , Anaphylaxis/epidemiology , Retrospective Studies , Immunization Programs , Skin Tests , Italy/epidemiologyABSTRACT
BACKGROUND: Moderate-to-severe atopic dermatitis (AD) in the adolescence is a high burden disease, and its treatment can be very challenging due to paucity of approved systemic drugs for this age and their side-effects. Dupilumab was recently approved for treatment of adolescent AD. OBJECTIVES: A multicentre, prospective, real-world study on the effectiveness and safety of dupilumab in adolescents (aged from ≥12 to <18 years) with moderate-to-severe AD was conducted. The main AD clinical phenotypes were also examined. METHODS: Data of adolescents with moderate-to-severe AD treated with dupilumab at label dosage for 16 weeks were collected. Treatment outcome was assessed by EASI, NRS itch, NRS sleep loss and CDLQI scores at baseline and after 16 weeks of treatment. The clinical scores were also evaluated according to clinical phenotypes. RESULTS: One hundred and thirty-nine adolescents were enrolled in the study. Flexural eczema and head and neck eczema were the most frequent clinical phenotypes, followed by hand eczema and portrait-like dermatitis. Coexistence of more than 1 phenotype was documented in 126/139 (88.5%) adolescents. Three patients (2.1%) contracted asymptomatic SARS-CoV-2 infection and 1 of the discontinued dupilumab treatment before the target treatment period. A significant improvement in EASI, NRS itch, NRS sleep loss and CDLQI was observed after 16 weeks of treatment with dupilumab. This outcome was better than that observed in clinical trials. Dupilumab resulted effective in all AD phenotypes, especially in diffuse eczema. Twenty-eight (20.1%) patients reported adverse events, conjunctivitis and flushing being the most frequent. None of patients discontinued dupilumab due to adverse event. CONCLUSIONS: Dupilumab in adolescent AD showed excellent effectiveness at week 16 with consistent improvement of all clinical scores. Moreover, dupilumab showed a good safety profile also in this COVID-19 pandemic era.
Subject(s)
COVID-19 Drug Treatment , Dermatitis, Atopic , Eczema , Antibodies, Monoclonal, Humanized , Dermatitis, Atopic/drug therapy , Double-Blind Method , Humans , Pandemics , Prospective Studies , Pruritus , SARS-CoV-2 , Severity of Illness Index , Treatment OutcomeABSTRACT
BACKGROUND: Dupilumab has proven to be an effective treatment for patients with moderate-to-severe atopic dermatitis (AD) in clinical trials. However, real-world experience with dupilumab in a broader population is limited. METHODS: The study population comprised adult patients with moderate-to-severe AD, defined as an Eczema Area Severity Index (EASI) score of 24 or higher, treated with dupilumab at 10 Italian teaching hospitals. We analyzed physician-reported outcome measures (EASI), patient-reported outcome measures (pruritus and sleep score, Dermatology Life Quality Index [DLQI]), and serological markers (IgE and eosinophil count) after 16 weeks. RESULTS: We enrolled 543 patients with moderate-to-severe AD. Two patients (0.4%) discontinued treatment. The median (IQR) change from baseline to 16 weeks of treatment in the EASI score was -87.5 (22.0) (P<.001). The EASI-50, EASI-75, and EASI-90 response rates were 98.1%, 81.5%, and 50.8% after 16 weeks. At 16 weeks, 93.0% of the patients had achieved a 4-point or higher improvement in DLQI from baseline. During treatment with dupilumab, 12.2% of the patients developed conjunctivitis, and total IgE decreased significantly (P<.001). Interestingly, in the multivariate logistic regression model, the risk of developing dupilumab-related conjunctivitis was associated with early onset of AD (OR, 2.25; 95%CI, 1.07-4.70; P=.03) and presence of eosinophilia (OR, 1.91; 95%CI, 1.05-3.39; P=.03). CONCLUSION: This is the broadest real-life study in AD patients treated with dupilumab to date. We observed more significant improvements induced by dupilumab in adult patients with moderate-to-severe AD than those reported in clinical trials.
Subject(s)
Conjunctivitis , Dermatitis, Atopic , Adult , Antibodies, Monoclonal, Humanized , Dermatitis, Atopic/drug therapy , Humans , Immunoglobulin E , Retrospective Studies , Severity of Illness Index , Treatment OutcomeABSTRACT
Background: Dupilumab has proven to be an effective treatment for patients with moderate-to-severe atopic dermatitis (AD) in clinical trials. However, real-world experience with dupilumab in a broader population is limited.Methods: The study population comprised adult patients with moderate-to-severe AD, defined as an Eczema Area Severity Index (EASI) score of 24 or higher, treated with dupilumab at 10 Italian teaching hospitals. We analyzed physician-reported outcome measures (EASI), patient-reported outcome measures (pruritus and sleep score, Dermatology Life Quality Index [DLQI]), and serological markers (IgE and eosinophil count) after 16 weeks.Results: We enrolled 543 patients with moderate-to-severe AD. Two patients (0.4%) discontinued treatment. The median (IQR) change from baseline to 16 weeks of treatment in the EASI score was 87.5 (22.0) (P<.001). The EASI-50, EASI-75, and EASI-90 response rates were 98.1%, 81.5%, and 50.8% after 16 weeks. At 16 weeks, 93.0% of the patients had achieved a 4-point or higher improvement in DLQI from baseline. During treatment with dupilumab, 12.2% of the patients developed conjunctivitis, and total IgE decreased significantly (P<.001). Interestingly, in the multivariate logistic regression model, the risk of developing dupilumab-related conjunctivitis was associated with early onset of AD (OR, 2.25; 95%CI, 1.07-4.70; P=.03) and presence of eosinophilia (OR, 1.91; 95%CI, 1.05-3.39; P=.03).Conclusion: This is the broadest real-life study in AD patients treated with dupilumab to date. We observed more significant improvements induced by dupilumab in adult patients with moderate-to-severe AD than those reported in clinical trials (AU)
Antecedentes: Se ha demostrado en ensayos clínicos que dupilumab es un tratamiento eficaz para pacientes con dermatitis atópica (DA)de moderada a grave. Sin embargo, la experiencia en vida real con dupilumab y con gran número de pacientes es más limitada.Métodos: Se incluyeron en el estudio pacientes adultos con DA de moderada a grave, definida como un índice de gravedad del área deeccema (EASI) de 24 o más, tratados con dupilumab en diez centros universitarios italianos. Se analizaron parámetros medidos por elmédico (EASI), por el paciente (puntuación de prurito y sueño, índice de calidad de vida dermatológica DLQI) y marcadores serológicos(inmunoglobulina IgE y recuento de eosinófilos en sangre) a las 16 semanas de tratamiento.Resultados: Se incluyeron 543 pacientes con DA de moderada a grave. Dos pacientes (0,4%) interrumpieron el tratamiento. La mediana± cambio porcentual intercuartílico desde el inicio hasta las 16 semanas de tratamiento en la puntuación EASI fue de -87,5 ± 22,0(p <0,001). Las tasas de respuesta de EASI-50, EASI-75 y EASI-90 fueron del 98,1%, 81,5% y 50,8% después de 16 semanas. En lasemana 16, el 93% de los pacientes habían logrado una mejora de 4 puntos o más en el DLQI desde el inicio. Durante el tratamiento condupilumab, el 12,2% de los pacientes desarrollaron conjuntivitis y la IgE total disminuyó significativamente (p <0,001). Curiosamente, enel modelo de regresión logística multivariante, el riesgo de desarrollar conjuntivitis relacionada con dupilumab se asoció con la aparicióntemprana de DA (OR, 2,25; IC del 95%, 1,074,70; p = 0,03) y presencia de eosinofilia (OR, 1,91; IC del 95%, 1,053,39; p = 0,03).Conclusión: Hasta la fecha, este es el estudio más amplio en vida real en pacientes con DA tratados con dupilumab. Se observaron mejorassignificativas y más importantes que las notificadas en los ensayos clínicos realizados con dupilumab (AU)
Subject(s)
Humans , Adult , Dermatitis, Atopic/drug therapy , Antibodies, Monoclonal, Humanized/administration & dosage , Risk Factors , Prognosis , Immunoglobulin E , Severity of Illness Index , Treatment Outcome , Conjunctivitis/chemically inducedABSTRACT
BACKGROUND: Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known. OBJECTIVES: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥65 years and affected by severe AD. Their main clinical features were also examined. METHODS: Data of elderly patients with severe (EASI ≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS and DLQI) scores at baseline and after 16 weeks of treatment. RESULTS: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis. The coexistence of more than one phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18-64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event. CONCLUSIONS: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.
Subject(s)
Dermatitis, Atopic , Eczema , Adolescent , Adult , Aged , Antibodies, Monoclonal, Humanized , Dermatitis, Atopic/drug therapy , Humans , Middle Aged , Retrospective Studies , Severity of Illness Index , Young AdultSubject(s)
Dermatitis, Atopic , Eczema , Adult , Antibodies, Monoclonal, Humanized , Dermatitis, Atopic/drug therapy , HumansSubject(s)
Dermatitis, Atopic/diagnosis , Dermatitis, Atopic/epidemiology , Adult , Humans , Phenotype , Prevalence , Public Health SurveillanceABSTRACT
Summary: A systematic review of the current literature on retreatment with omalizumab of patients with relapsing chronic spontaneous urticaria was performed. Published evidence shows that retreatment is safe and clinically effective, and that time to complete clinical response reduces as the number of retreatments increases.
Subject(s)
Anti-Allergic Agents/therapeutic use , Chronic Urticaria/drug therapy , Omalizumab/therapeutic use , Drug-Related Side Effects and Adverse Reactions , Humans , Treatment OutcomeSubject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Conjunctivitis/epidemiology , Dermatitis, Atopic/epidemiology , Drug-Related Side Effects and Adverse Reactions/epidemiology , Adult , Antibodies, Monoclonal, Humanized/therapeutic use , Conjunctivitis/etiology , Female , Humans , Incidence , Italy/epidemiology , Male , Prevalence , Risk FactorsABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Adult , Dermatitis, Atopic/classification , Phenotype , Severity of Illness Index , Retrospective Studies , PrevalenceABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Adult , Dermatitis, Atopic/drug therapy , Conjunctivitis/chemically induced , Antibodies, Monoclonal/adverse effects , Dermatologic Agents/adverse effects , Severity of Illness Index , Antibodies, Monoclonal/therapeutic use , Dermatologic Agents/therapeutic use , Prospective Studies , Risk FactorsABSTRACT
BACKGROUND: Chronic spontaneous urticaria (CSU) is defined as spontaneous occurrence of wheals and/or angioedema for ≥6 weeks. Omalizumab is a monoclonal anti-IgE antibody effective in refractory CSU, but its mechanism of action and markers predictive of response remain not completely defined. OBJECTIVES: To correlate baseline levels of two proposed biomarkers, total IgE (bIgE) and d-dimer (bd-dimer), and clinical parameters to omalizumab response and to relapses after drug withdrawal. METHODS: In this retrospective Italian multicentre study, clinical data were collected in 470 CSU patients, and bIgE and bd-dimer were measured in 340 and 342 patients, respectively. Disease activity was determined by Urticaria Activity Score 7 (UAS7) at week 1 and 12 after omalizumab starting. Relapses were evaluated during a 2- and 3-month interval after a first and a second course of treatment, respectively. RESULTS: bIgE correlated to a good response to omalizumab since levels were significantly higher in responders than non-responders (P = 0.0002). Conversely, bd-dimer did not correlate to response. There was no correlation between both bIgE and d-dimer and either first or second relapse. Disease duration was significantly longer in patients who experienced either first or second relapse (P < 0.0001 and P = 0.0105, respectively), while baseline UAS7 correlated only to first relapse (P = 0.0023). CONCLUSIONS: Our study confirms bIgE as a reliable biomarker predicting response to omalizumab in CSU, while it does not support the usefulness of bd-dimer unlike previous findings. CSU duration before omalizumab and baseline UAS7 may be clinical markers of relapse risk.
Subject(s)
Anti-Allergic Agents/therapeutic use , Omalizumab/therapeutic use , Urticaria/drug therapy , Adult , Biomarkers/blood , Chronic Disease , Female , Fibrin Fibrinogen Degradation Products/metabolism , Humans , Immunoglobulin E/blood , Italy , Male , Middle Aged , Recurrence , Retrospective Studies , Treatment Outcome , Urticaria/blood , Urticaria/physiopathologyABSTRACT
Adverse reactions (ARs) to drugs administered during general anesthesia may be very severe and life-threatening, with a mortality rate ranging from 3 to 9%. The adverse reactions to drugs may be IgE and non-IgE-mediated. Neuromuscular blocking agents (NMBA) represent the first cause of perioperative reactions during general anesthesia followed by latex, antibiotics, hypnotic agents, opioids, colloids, dyes and antiseptics (chlorhexidine). All these substances (i.e. NMBA, anesthetics, antibiotics, latex devices) may cause severe systemic non-IgE-mediated reactions or fatal anaphylactic events even in the absence of any evident risk factor in the patient's anamnesis. For this reason, in order to minimize perioperative anaphylactic reactions, it is important to have rapid, specific, sensitive in vitro diagnostic tests able to confirm the clinical diagnosis of acute anaphylaxis.
ABSTRACT
This evidence- and consensus-based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. The conference was held on 1 December 2016. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the EU-founded network of excellence, the Global Allergy and Asthma European Network (GA²LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO) with the participation of 48 delegates of 42 national and international societies. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease, presenting with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous urticaria and other chronic forms of urticaria are disabling, impair quality of life and affect performance at work and school. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms. In addition, it outlines evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.
Subject(s)
Urticaria/diagnosis , Urticaria/therapy , Disease Management , Europe , Health Services Needs and Demand , Humans , Research , Urticaria/etiologyABSTRACT
No disponible
Subject(s)
Humans , Latex Hypersensitivity/diagnosis , Dermatitis, Allergic Contact/diagnosis , Quality of Life , Sickness Impact Profile , Occupational Exposure/analysis , Dermatitis, Occupational/diagnosisABSTRACT
Acrylates and methacrylates are a large group of chemically reactive monomers that are polymerized into acrylic plastics. These have very broad applications in glues, coatings and various plastic materials. Allergic contact dermatitis (ACD) caused by acrylates can be occupational, mainly in dentistry workers during the manufacturing and implantation of dental prosthesis, and in nail technicians during the sculpturing and application of artificial nails. The clinical manifestations vary according to the location of the contact. In non-occupational ACD, hand eczema, pulpitis and stomatitis are more frequent. We conducted a study to investigate the frequency of sensitization to acrylates, determining the most frequently sensitizing acrylates and assessing the possible role of 2-hydroxyethyl methacrylate (2-HEMA) as a screening allergen. From January 2013 to December 2014, 217 patients with a personal history and symptoms suggestive of contact dermatitis were patch tested with an extended series of acrylates at the Dermatology and Allergology Units of the University Hospital of Bari. Seven patients (3.2%) had positive reactions. The reactions were related to artificial nails in 2 patients (28.6%), both beauticians, and dental material in 5 patients (71.4%) with dental prosthesis. 2-HEMA detected 100%of sensitized patients to acrylates.